首页> 美国卫生研究院文献>NeuroRx >A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (Line 61) Mice
【2h】

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (Line 61) Mice

机译:帕金森氏病的渐进性小鼠模型:Thy1-aSyn( 61行)小鼠

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Identification of mutations that cause rare familial forms of Parkinson’s disease (PD) and subsequent studies of genetic risk factors for sporadic PD have led to an improved understanding of the pathological mechanisms that may cause nonfamilial PD. In particular, genetic and pathological studies strongly suggest that alpha-synuclein, albeit very rarely mutated in PD patients, plays a critical role in the vast majority of individuals with the sporadic form of the disease. We have extensively characterized a mouse model over-expressing full-length, human, wild-type alpha-synuclein under the Thy-1 promoter. We have also shown that this model reproduces many features of sporadic PD, including progressive changes in dopamine release and striatal content, alpha-synuclein pathology, deficits in motor and nonmotor functions that are affected in pre-manifest and manifest phases of PD, inflammation, and biochemical and molecular changes similar to those observed in PD. Preclinical studies have already demonstrated improvement with promising new drugs in this model, which provides an opportunity to test novel neuroprotective strategies during different phases of the disorder using endpoint measures with high power to detect drug effects.Electronic supplementary materialThe online version of this article (doi:10.1007/s13311-012-0104-2) contains supplementary material, which is available to authorized users.
机译:对引起罕见家族性帕金森氏病(PD)的突变的鉴定以及对散发性PD的遗传危险因素的后续研究使人们对可能引起非家族性PD的病理机制有了更深入的了解。特别是,遗传和病理学研究强烈表明,尽管在PD患者中很少发生突变,但α-突触核蛋白在绝大多数散发性疾病中起着至关重要的作用。我们已经广泛地描述了在Thy-1启动子下过表达全长,人类,野生型α-突触核蛋白的小鼠模型。我们还显示,该模型重现了散发性PD的许多特征,包括多巴胺释放和纹状体含量的逐步变化,α-突触核蛋白病理学,PD的预示阶段和明显阶段受到影响的运动和非运动功能缺陷,炎症,生物化学和分子变化与PD相似。临床前研究已经表明,在该模型中使用有前途的新药可以改善临床表现,这提供了一个机会,可以使用具有检测药物作用的强大功效的终点检测方法,在疾病的不同阶段中测试新的神经保护策略。电子补充材料本文的在线版本(doi :10.1007 / s13311-012-0104-2)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号